Meeting
2021 ASCO Annual Meeting
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
Authors
Salma K. Jabbour
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Salma K. Jabbour , Byoung Chul Cho , Emilio Bria , Terufumi Kato , Jaishree Bhosle , Justin F. Gainor , Noemi Reguart , Luhua Wang , Daniel Morgensztern , Ellen Gurary , Tanya B. Ashraf , Humberto Lara-Guerra , Martin Reck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04380636
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS8580)
DOI
10.1200/JCO.2021.39.15_suppl.TPS8580
Abstract #
TPS8580
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2023 ASCO Annual Meeting
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
First Author: Fabrice Barlesi
Poster
2021 ASCO Annual Meeting
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
First Author: Andreas Rimner
Poster
2019 ASCO Annual Meeting
Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).
First Author: Luis G. Paz-Ares